Pulmatrix, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Pulmatrix, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $7.91M | Mar 26, 2020 |
| FY2019 | Dec 31, 2018 | $153.0K | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $335.0K | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $835.0K | Mar 13, 2018 |
| FY2016 | Dec 31, 2015 | $1.20M | Mar 10, 2017 |
| FY2015 | Mar 31, 2015 | $0 | Jun 10, 2015 |
| FY2015 | Dec 31, 2014 | $352.0K | Mar 10, 2016 |
| FY2015 | Mar 31, 2014 | $0 | Jun 10, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $7.81M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $7.30M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $6.07M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $5.17M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $12.63M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $7.91M | Mar 23, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.16M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($9.56M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($14.12M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($18.84M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($20.17M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($19.31M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($20.60M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($20.56M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($18.06M) | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | ($27.84M) | Mar 13, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.17M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($9.76M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($14.74M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($18.95M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($20.17M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($9.86M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($20.69M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($20.40M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($17.48M) | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | ($24.87M) | Mar 13, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $7.17M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $15.52M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $18.24M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $15.38M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $15.61M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $12.85M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $12.97M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $10.24M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $10.15M | Mar 13, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Mar 31, 2015 | $4.53M | Jun 10, 2015 |
| FY2015 | Mar 31, 2014 | $1.74M | Jun 10, 2015 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.43M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($10.72M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($15.99M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($19.36M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($19.73M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($12.48M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $3.23M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($16.76M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($14.48M) | Feb 19, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $398.0K | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $676.0K | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $86.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $144.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $281.0K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $58.0K | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $19.0K | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $74.0K | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $455.0K | Mar 13, 2018 |
| FY2016 | Dec 31, 2015 | $266.0K | Mar 10, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.14M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $9.94M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $33.96M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $40.95M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $58.82M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $38.10M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $36.10M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $14.72M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $15.98M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $16.66M | Mar 13, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $329.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $996.0K | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $15.96M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $9.84M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $11.37M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $14.96M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $25.08M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $2.88M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $5.84M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $7.90M | Mar 13, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.81M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $8.95M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $18.00M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $31.11M | Mar 21, 2025 |
| FY2023 | Dec 31, 2021 | $47.45M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $23.14M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $11.02M | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | $11.84M | Mar 23, 2021 |
| FY2019 | Dec 31, 2017 | $10.14M | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | $8.76M | Feb 19, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | $3.58M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $3.58M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $10.85M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $10.91M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $10.91M | Mar 13, 2018 |
| FY2017 | Dec 31, 2015 | $15.94M | Mar 13, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($302.32M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($297.16M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($287.60M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($273.48M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($254.64M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($234.47M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($215.16M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($194.57M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($174.00M) | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | ($155.95M) | Mar 13, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.09M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $9.52M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $19.17M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $35.63M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $53.84M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $31.66M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $23.44M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $2.56M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $3.55M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $4.18M | Mar 13, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (8) | Mar 30, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Mar 28, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.65M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 3.65M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 3.65M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | 3.64M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 3.22M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 1.81M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | 19.99M | Mar 23, 2021 |
| FY2020 | Feb 5, 2019 | 10 | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | 4.92M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | 2.10M | Feb 19, 2019 |